Business Context and Reporting Period
This Form 8-K was filed by Recursion Pharmaceuticals, Inc. on December 15, 2023. The report details a corporate event regarding the registration of shares for resale rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a securities transaction.
Material Changes and Events
- Share Registration: Recursion filed a prospectus supplement to register for resale 3,225,902 shares of Class A common stock.
- Transaction Counterparty: The shares were issued to Tempus Labs, Inc. ("Tempus").
- Consideration: The shares were issued in payment for an initial license fee under a Master Agreement between Recursion and Tempus.
- Reference: The underlying agreement was previously disclosed in an 8-K filed on November 9, 2023.
- Legal Basis: The offering was made pursuant to an exemption from registration under the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It does not disclose new risks or contingencies beyond the standard legal opinion regarding the legality of the resale shares.
Investor Verification Checklist
- Verify the terms of the Master Agreement with Tempus Labs referenced in the November 9, 2023, 8-K filing.
- Confirm the valuation of the 3,225,902 shares issued as payment for the license fee.
- Review the legal opinion filed as Exhibit 5.1 regarding the legality of the resale shares.
- Check for any subsequent filings regarding the actual sale or trading of these registered shares.